AFM-28

N/A

Report date: 2022/12/23 09:36:19

Base Information

Drug NameAFM-28
Drug Alias NameAFM-28
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD123FCGR3A (CD16a) NK-cell engagers
TargetsInterleukin-3 receptor subunit alphaLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFranceSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAffimed
China Registration ClassN/A

Develop Information

Active CompaniesAffimed Nv
Inactive CompaniesAffimedAffimed Gmbh
Active IndicationsLeukemia, Promyelocytic, Acute
Inactive IndicationsLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A